- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01431521
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
August 10, 2018 updated by: Merck Sharp & Dohme LLC
An Exploratory Study to Evaluate Changes in Hepatic Fat Following Multiple-Dose Administration of MK-4074 and Pioglitazone Hydrochloride
This study will evaluate changes in liver fat content following multiple oral doses of MK-4074 and Pioglitazone Hydrochloride in adult males and females with fatty liver disease.
The primary hypothesis of the study is that a multiple-dose administration of MK-4074 200 mg twice daily for 4 weeks results in a decrease in hepatic fat content with respect to placebo in adult male and female participants with hepatic steatosis (i.e., on order of 50% reduction in hepatic fat with respect to placebo is expected).
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Females must be of non-childbearing potential
- Body mass index (BMI) ≥32.0 kg/m^2
- In good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests
- No clinically significant abnormality on electrocardiogram
- Has documented hepatic fat content ≥10% within 6 months of enrollment
- Maintained stable weight (by history) for at least 4 weeks
- Agrees not to initiate a weight loss program and agrees to maintain consistent dietary habits and exercise routines for the duration of the study
- Has a rating of 'moderate' or 'severe' steatosis on ultrasound at the prestudy (screening) visit
Exclusion Criteria:
- Change in weight greater than 4% between prestudy visit and randomization into the study
- History of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the participant
- Liver disease other than fatty liver or non-alcoholic steatohepatitis (NASH)
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3x the upper limit of normal range
- Serum triglyceride level >600 mg/dL
- History of stroke, chronic seizures, or major neurological disorder
- History of clinically significant endocrine, gastrointestinal, cardiovascular (including congestive heart failure), hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
- Had abdominal surgery, gastric bypass, bowel resection, recent liver biopsy, or any other procedure within a minimum of 4 weeks
- History of neoplastic disease
- Claustrophobia or other contraindication to magnetic resonance imaging (MRI)
- Have not washed off agents associated with changes in hepatic fat or used for treatment of Non-alcoholic fatty liver disease (NAFLD) or NASH for a minimum of 3 months prior
- Consumes excessive amounts of alcohol, coffee, tea, cola, or other caffeinated beverages
- Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another investigational study within 4 weeks
- Significant multiple and/or severe allergies
- Intolerance or hypersensitivity to pioglitazone hydrochloride or any inactive ingredients
- Regular user of any illicit drugs or has a history of drug (including alcohol) abuse.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MK-4074
Participants will receive oral doses of MK-4074 200 mg (2 x 100-mg capsules) twice daily for 4 weeks.
|
2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks
|
PLACEBO_COMPARATOR: Placebo for MK-4074
Participants will receive oral doses of placebo to match MK-4074 twice daily for 4 weeks.
|
2 x 100-mg capsules, orally, BID for 4 weeks.
|
EXPERIMENTAL: Pioglitazone
Participants will receive oral doses of pioglitazone hydrochloride 30 mg (1 x 30-mg tablet) once daily for 4 weeks.
|
1 x 30-mg tablet, orally, once daily for 4 weeks
|
PLACEBO_COMPARATOR: Placebo for pioglitazone
Participants will receive oral doses of placebo to match pioglitazone hydrochloride once daily for 4 weeks.
|
1 x 30-mg tablet, orally, once daily for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Hepatic Fat
Time Frame: Baseline and Week 4
|
Hepatic fat content was assessed via magnetic resonance imaging (MRI) prior to first dose administration and following 4 weeks of treatment.
Percent change in hepatic fat fraction from baseline was calculated for each of the 9 liver regions separately and then these were averaged to calculate overall percent change from baseline for each participant.
|
Baseline and Week 4
|
Number of Participants Experiencing One or More Adverse Events (AE)
Time Frame: Up to 10 weeks
|
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
|
Up to 10 weeks
|
Number of Participants Who Discontinued Study Drug Due to an AE
Time Frame: Up to 4 weeks
|
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
|
Up to 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Alanine Transaminase (ALT)
Time Frame: Baseline and Week 4
|
Hepatic steatosis is not uncommonly associated with mild elevations in serum transaminases, specifically ALT, and these elevations may be a marker of more advanced hepatic disease.
Serum transaminases were monitored at baseline and once weekly for the duration of the study to permit a better understanding of the time course of potential improvement in hepatic inflammation during the course of this short study.
|
Baseline and Week 4
|
Percent Change From Baseline Aspartate Transaminase (AST)
Time Frame: Baseline and Week 4
|
Hepatic steatosis is not uncommonly associated with mild elevations in serum transaminases, including AST, and these elevations may be a marker of more advanced hepatic disease.
Serum transaminases were monitored at baseline and once weekly for the duration of the study to permit a better understanding of the time course of potential improvement in hepatic inflammation during the course of this short study.
|
Baseline and Week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 26, 2011
Primary Completion (ACTUAL)
September 18, 2012
Study Completion (ACTUAL)
October 1, 2012
Study Registration Dates
First Submitted
September 7, 2011
First Submitted That Met QC Criteria
September 7, 2011
First Posted (ESTIMATE)
September 9, 2011
Study Record Updates
Last Update Posted (ACTUAL)
September 10, 2018
Last Update Submitted That Met QC Criteria
August 10, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4074-008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-alcoholic Fatty Liver Disease
-
Naga P. ChalasaniDSM Nutritional Products, Inc.CompletedNon-Alcoholic Fatty Liver Disease | Non-Alcoholic Steatohepatitis | Non-Alcoholic Fatty LiverUnited States
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Michael Ohliger, MD PhDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingNAFLD | Non-Alcoholic Fatty Liver Disease | NASH | Non Alcoholic Fatty Liver | Non Alcoholic SteatohepatitisUnited States
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
Nehal Abou SeadaCompletedNon-Alcoholic Fatty Liver Disease
-
Better TherapeuticsArizona Liver HealthCompletedNon-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty LiverUnited States
-
Puerta de Hierro University HospitalHospital Universitario Marqués de ValdecillaNot yet recruitingNon-Alcoholic Fatty Liver Disease | Non Alcoholic SteatohepatitisSpain
-
BASF ASUnknownNASH - Nonalcoholic Steatohepatitis | Non-Alcoholic Fatty Liver Disease | Non Alcoholic Fatty LiverUnited States
-
National University Hospital, SingaporeWilmar InternationalEnrolling by invitationNAFLD | Non-Alcoholic Fatty Liver Disease | Non-Alcoholic SteatohepatitisSingapore
-
AB Biotics, SACompletedNon Alcoholic Fatty LiverMexico
Clinical Trials on MK-4074 200 mg
-
Merck Sharp & Dohme LLCCompletedHepatitis C Virus Infection
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedHypertension | Isolated Systolic Hypertension (ISH)
-
Yuhan CorporationCompleted
-
Merck Sharp & Dohme LLCTerminatedNeoplasm MetastasisUnited States, Canada, Israel
-
Mylan Pharmaceuticals IncCompletedHealthyUnited States
-
Novartis PharmaceuticalsRecruitingNon-Small Cell Lung CarcinomaIndia
-
Merck Sharp & Dohme LLCCompleted